Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 08 2021
12 08 2021
Historique:
received:
26
04
2021
accepted:
30
07
2021
entrez:
13
8
2021
pubmed:
14
8
2021
medline:
16
11
2021
Statut:
epublish
Résumé
To date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosterone (TT) serum levels in 67 mPC patients monitored between April 2008 and November 2020. FT and TT levels were measured before and weekly during therapy. The primary endpoint was overall survival (OS). Secondary endpoints were prostate-specific antigen response and radiographic response (PSAR, RR), progression-free survival (PFS), FT/TT levels and safety. Median FT and TT serum levels were completely suppressed to below the detection limit during docetaxel treatment (FT: from 0.32 to < 0.18 pg/mL and TT: from 0.12 to < 0.05 ng/mL, respectively). Multivariate Cox regression analyses identified requirement of non-narcotics, PSAR, complete FT suppression and FT nadir values < 0.18 pg/mL as independent parameters for PFS. Prior androgen-receptor targeted therapy (ART), soft tissue metastasis and complete FT suppression were independent prognostic factors for OS. FT was not predictive for treatment outcome in mPC patients with a history of ART.
Identifiants
pubmed: 34385568
doi: 10.1038/s41598-021-95874-y
pii: 10.1038/s41598-021-95874-y
pmc: PMC8361102
doi:
Substances chimiques
Antineoplastic Agents
0
Docetaxel
15H5577CQD
Testosterone
3XMK78S47O
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16457Informations de copyright
© 2021. The Author(s).
Références
Int J Biol Markers. 2005 Apr - Jun;20(2):119-222
pubmed: 28207137
J Clin Oncol. 2013 Aug 10;31(23):2963-9
pubmed: 23835712
Eur Urol. 2014 Oct;66(4):646-52
pubmed: 24491307
Cancer Res. 2008 Jun 1;68(11):4447-54
pubmed: 18519708
J Biochem. 1987 Sep;102(3):493-501
pubmed: 3429444
Annu Rev Med. 2019 Jan 27;70:479-499
pubmed: 30691365
J Clin Oncol. 1989 May;7(5):590-7
pubmed: 2709088
Cancer Res. 1996 Mar 15;56(6):1296-302
pubmed: 8640817
BMC Med Res Methodol. 2010 Mar 16;10:20
pubmed: 20233435
Eur Urol Oncol. 2018 Dec;1(6):467-475
pubmed: 31158090
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Chemother Pharmacol. 2004 Sep;54(3):219-29
pubmed: 15175893
J Clin Oncol. 2010 Oct 20;28(30):4562-7
pubmed: 20855838
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38
pubmed: 30131604
J Clin Oncol. 2014 Mar 1;32(7):671-7
pubmed: 24449231
N Engl J Med. 2018 Feb 15;378(7):645-657
pubmed: 29412780
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Arch Biochem Biophys. 1997 Oct 1;346(1):161-9
pubmed: 9328296
Urol Oncol. 1996 Mar-Apr;2(2):70-3
pubmed: 21224139
Urology. 2014 Jun;83(6):1217-22
pubmed: 24713136
Eur Urol. 2020 Apr;77(4):508-547
pubmed: 32001144
Prostate. 2019 Aug;79(11):1211-1220
pubmed: 31251826
Front Horm Res. 2009;37:21-31
pubmed: 19011286
Cancer Res. 2009 Nov 1;69(21):8386-94
pubmed: 19826044
J Clin Oncol. 2008 Mar 1;26(7):1148-59
pubmed: 18309951
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):66-73
pubmed: 31053766
Oncol Lett. 2017 Jan;13(1):22-28
pubmed: 28123517
J Clin Oncol. 2013 Aug 1;31(22):2791-8
pubmed: 23816964
Eur Urol. 2017 Apr;71(4):656-664
pubmed: 27402060
Ann Oncol. 2012 Nov;23(11):2943-2947
pubmed: 22771826